Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Fate Therapeutics, Inc.NASDAQ: FATE

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns negative

Q1 FY2026 Accumulated OCI was -$77K, compared with $191K a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -140.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$77K-166.4% QoQ
Last fiscal yearDec 2025
$116K-56.7% YoY
Year agoMar 2025
$191K-140.3% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-140.3%——
1 year-56.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
116K USD
Year-over-year change
-56.7%

Accumulated OCI vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -140.3% is the 4th highest of 9, against a peer median of -161.3%.
  • Accumulated OCI amounts to 0.0% of total assets for FATE, versus a peer median of 0.0%.
FATE Competitors
Accumulated OCI for FATE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$21K USD+40.0%—0.0%
MOLNMolecular Partners AGMar 2026CHF 0 CHF——0.0%
PRLDPrelude Therapeutics IncorporatedMar 2026-$41K USD-441.7%—0.0%
PEPGPepGen Inc.Mar 2026-$59K USD-168.2%—0.0%
FATEFate Therapeutics, Inc.Mar 2026-$77K USD-140.3%—0.0%
ALECAlector, Inc.Mar 2026-$104K USD-154.5%—0.0%
NKTXNkarta, Inc.Mar 2026-$130K USD-119.9%—0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026-$161K USD-600.0%—0.1%
INOInovio Pharmaceuticals, Inc.Mar 2026-$636.09K USD+3.8%—1.3%
VORVor Biopharma Inc.Mar 2026-$706K USD-3169.6%—0.1%
Peer median (excluding FATE) —-161.3%—0.0%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents133.58M61.33M41.87M36.06M46.63M
Short-term Investments482.33M374.89M273.31M243.01M157.03M
Net Receivables8.68M38.48M1.83M3.54M916K
Inventory00000
Other Current Assets1.1M27.37M900K9.3M4.13M
Total Current Assets633.41M502.07M331.54M291.91M208.7M
Property, Plant & Equipment (Net)162.25M66.07M158.51M110.89M98.53M
Goodwill00000
Intangible Assets00000
Long-term Investments100.66M4.94M980K27.66M1.47M
Tax Assets00000
Other Non-current Assets25.13M132.48M15.19M10.24M10.23M
Total Non-current Assets288.04M203.49M174.68M148.79M110.23M
Total Assets921.46M705.56M506.22M440.69M318.94M
Account Payables8.61M8.27M4.72M9.37M2.66M
Short-term Debt006.18M00
Tax Payables00000
Deferred Revenue21.48M42.23M685K393K381K
Other Current Liabilities3.2M40.03M16.95M11.64M8.45M
Total Current Liabilities81.28M114.05M39.09M38.52M36.07M
Long-term Debt000073.29M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)27.12M0000
Other Non-current Liabilities24.97M3.86M1.35M5.6M2.4M
Total Non-current Liabilities161.33M107.57M98.71M83.45M75.68M
Total Liabilities242.62M221.62M137.8M121.97M111.75M
Common Stock96K97K99K114K115K
Retained Earnings(769.08M)(1.05B)(1.21B)(1.4B)(1.53B)
Accumulated OCI(762K)(1.85M)15K268K116K
Other Stockholders Equity00(0)01.74B
Minority Interest00000
Total Equity678.84M483.94M368.42M318.73M207.18M
Total Debt114.82M109.34M103.54M85.27M77.85M
Net Debt(18.77M)48.01M61.67M49.21M31.22M

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.